Goldenwell Biotech Changes Certifying Accountant
Ticker: GWLL · Form: 8-K · Filed: Jan 23, 2025 · CIK: 1800373
| Field | Detail |
|---|---|
| Company | Goldenwell Biotech, INC. (GWLL) |
| Form Type | 8-K |
| Filed Date | Jan 23, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: auditor-change, corporate-governance
Related Tickers: GDWL
TL;DR
GDWL changed its auditor effective Jan 23, 2025.
AI Summary
Goldenwell Biotech, Inc. filed an 8-K on January 23, 2025, to report a change in its certifying accountant. The company has appointed a new independent registered public accounting firm, effective January 23, 2025. This change is disclosed under Item 4.01 of the filing.
Why It Matters
A change in auditor can signal shifts in a company's financial reporting or internal controls, warranting investor attention.
Risk Assessment
Risk Level: low — This filing reports a routine administrative change in the company's auditor and does not involve financial performance or strategic shifts.
Key Players & Entities
- GOLDENWELL BIOTECH, INC. (company) — Registrant
- January 23, 2025 (date) — Date of earliest event reported
- Item 4.01 (filing_item) — Disclosure of change in certifying accountant
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a change in Goldenwell Biotech, Inc.'s certifying accountant, as disclosed under Item 4.01.
When was the change in the certifying accountant effective?
The change in the certifying accountant was effective on January 23, 2025.
What is the company's full name as stated in the filing?
The company's full name is Goldenwell Biotech, Inc.
In which state is Goldenwell Biotech, Inc. incorporated?
Goldenwell Biotech, Inc. is incorporated in Nevada.
What is the address of Goldenwell Biotech, Inc.'s principal executive offices?
The address of Goldenwell Biotech, Inc.'s principal executive offices is 581 Boston Mills Road, Suite 300, Hudson, Ohio 44087.
Filing Stats: 790 words · 3 min read · ~3 pages · Grade level 13.9 · Accepted 2025-01-23 17:20:36
Filing Documents
- gdwl_8k.htm (8-K) — 24KB
- gdwl_ex161.htm (EX-16.1) — 2KB
- 0001477932-25-000424.txt ( ) — 142KB
- gdwl-20250123.xsd (EX-101.SCH) — 6KB
- gdwl-20250123_lab.xml (EX-101.LAB) — 13KB
- gdwl-20250123_cal.xml (EX-101.CAL) — 1KB
- gdwl-20250123_pre.xml (EX-101.PRE) — 8KB
- gdwl-20250123_def.xml (EX-101.DEF) — 2KB
- gdwl_8k_htm.xml (XML) — 4KB
01 Changes in Registrant's Certifying Accountant
Item 4.01 Changes in Registrant's Certifying Accountant (a) On January 23, 2025, Goldenwell Biotech, Inc. (the "Company") notified Michael Gillespie & Associates, PLLC ("Michael Gillespie & Associates") that the Company had dismissed Michael Gillespie & Associates as the independent registered public accounting firm of the Company. The Board of Directors of the Company recommended and approved the dismissal. Michael Gillespie & Associates most recently served as the Company's independent registered public accounting firm from November 14, 2024, until January 23, 2025, and reviewed financial statements contained in one Quarterly Report on Form 10-Q, such Form 10-Q being for the fiscal quarter ended September 30, 2024. Michael Gillespie & Associates did not make or otherwise provide any reports regarding the Company's financial statements as of December 31, 2024 and 2023, or the related consolidated statements of operations and comprehensive loss, consolidated statements of changes in stockholders' equity, or consolidated statements of cash flows for the years then ended. During the period of engagement, from November 14, 2024, through the date of dismissal on January 23, 2025, the Company had no disagreement with Michael Gillespie & Associates on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure. There were no reportable events, as listed in Item 304(a)(1)(v) of Regulation S-K. The Company provided Michael Gillespie & Associates a copy of the above disclosures and requested Michael Gillespie & Associates to furnish a letter addressed to the Securities and Exchange Commission stating whether or not it agrees with the above statements. Michael Gillespie & Associates's response is attached as Exhibit 16.1 to this Current Report on Form 8-K. (b) On January 23, 2025, the board of directors of the Company resolved to engage the independent registered public accounting firm KCCW Accountancy Corp. ("KCCW")
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits: Exhibit Description 16.1 Letter from Michael Gillespie & Associates, PLLC, dated January 23, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GOLDENWELL BIOTECH, INC. Date: January 23, 2025 By: /s/ Shuang Liu Name: Shuang Liu Title: Chief Executive Officer 3